Medicinal application of long synthetic peptide technology

Bibliography

• SUBHASH S, SOE S, ROUSSILHON Cet al.: Characterization of functional antibodies to conserved regions of Plasmodium falcipamm MSP3 in order to improve vaccine design.' Infect. Dis. (2004) (In Press).
   Google Scholar
• UTHAILPIBULL C, AUFIERO B, SYED SE et al.: Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falcipamm. I MM. Biol. (2001) 307(5):1381–1394.
   PubMed Web of Science ®Google Scholar
• MERRIFIELD RB: Solid-phase peptide synthesis. 3. An improved synthesis of bradykinin. Biochemistry (1964) 14(9):1385–1390.
   Google Scholar
• ATHERTON E, SHEPPARD RC: Solid Phase Peptide Synthesis: A Practical Approach. Atherton E, Sheppard RC (Eds), IRL Press at Oxford University Press (1989).
   Google Scholar
• HENKEL B, BAYER E: Monitoring of solidphase peptide synthesis by FT-IR spectroscopy. Peptide Sci. (1998) 4:461–470.
   PubMed Web of Science ®Google Scholar
• RIVIER J, RIVIER C, SPIESS J, VALE W: High-performance liquid chromatographic purification of peptide hormones: ovine hypothalamic amunine (corticotropin releasing factor). Anal. Biochem. (1982) 127(2):258–266.
   PubMed Web of Science ®Google Scholar
• CLARK-LEWIS I, AEBERSOLD R, ZILTENER H et al.: Automated chemical synthesis of a protein growth factor for hemopoietic cells, interleukin-3. Science (1986) 231(4734):134–139.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER J, KENT SB: Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease. Cell (1988) 54(3):363–368.
   PubMed Web of Science ®Google Scholar
• HOEPRICH JR PD: Polypeptide/protein synthesis using Fmoc/t-butyl protectionstrategy. In: Innovation and Perspectives M Solid Phase Synthesis. Epton R (Ed.), Intercept Ltd, Andover, UK (1992):49–55.
   Google Scholar
• DAWSON PE, KENT SB: Synthesis of native proteins by chemical ligation. Anna. Rev Biochem. (2000) 69:923–960.
   PubMed Web of Science ®Google Scholar
• ROGGERO M, SERVIS C,CORRADIN G: A simple and rapid procedure for the purification of synthetic polypeptides by a combination of affinity chromatography and methionine chemistry. FEBS Lett. (1997) 408(3):285–288.
   PubMed Web of Science ®Google Scholar
• THIERRY AC, PERRENOUD G, PINAUD S et al: Biotinylated synthetic chemokines: their use for the development of nonradioactive whole-cell binding assays. Biomol Screen. (2003) 8(3):316–323.
   PubMed Web of Science ®Google Scholar
• SNYDER AP: Interpreting Protein Mass Spectra: A Comprehensive Resource. Snyder AP (Ed.), American Chemical Society, Washington DC, USA (2000).
   Google Scholar
• MUTTER M, NEFZI A, SATO T et al:Pseudo-prolines (psi Pro) for accessing 'inaccessible' peptides. Pept. Res. (1995) 8(3):145–153.
   PubMedGoogle Scholar
• SOLE. NA, BARANY G: Optmization of solid-phase peptide synthesis of [Ala8]-dynorphin A1-3. I Org. Chem. (1992) 57:5399–5403.
   Web of Science ®Google Scholar
• KING D, FIELDS CG, FIELDS GB: A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis. hat. I Peptide Protein Res. (1990) 35(3):284–286.
   PubMedGoogle Scholar
• ROGGERO MA, FILIPPI B, CHURCH P et al: Synthesis and immunological characterization of 104-mer and 102-mer peptide corresponding to the N- and C-terminal regions of the Plasmodium fakiparum CS protein. Ma. Immunol (1995) 32(12):1301–1309.
   PubMedGoogle Scholar
• CERAMI C, FREVERT U, SINNIS P et al: The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium fakiparum sporozoites. Cell (1992) 70(6):1021–1033.
   PubMed Web of Science ®Google Scholar
• CERAMI C, KWAKYE-BERKO F, NUSSENZWEIG V: Binding of malarial circumsporozoite protein to sulfatides [Gal(3-504)131-Cer] and cholesterol-3-sulfate and its dependence on disulfide bond formation between cysteines in region II. Ma. Biochem. Parasitol (1992) 54(1):1–11.
   PubMed Web of Science ®Google Scholar
• ROGGERO MA, MERALDI V,LOPEZ JA et al.: The synthetic, oxidized C-terminal fragment of the Plasmodium berghei circumsporozoite protein elicits a high protective response. Eur: .1. Immunol (2000) 30(9):2679–2685.
   Google Scholar
• MERALDI V, AUDRAN R, ROMERO JF et al: 0M-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242–310 from the circumsporozoite protein of Plasmodium berghei Vaccine (2003) 21(19–20):2485–2491.
   Google Scholar
• BLUM-TIROUVANZIAM U, BEGHDADI-RAIS C, ROGGERO MA et al: Elicitation of specific cytotoxic T cells by immunization with malaria soluble synthetic polypeptides. I Immunol (1994) 153(9):4134–4141.
   PubMed Web of Science ®Google Scholar
• LOPEZ JA, GONZALEZ JM,KETTNER A et al.: Synthetic peptides corresponding to the non-repeat regionsfrom the circumsporozoite protein of Plasmodium fakiparum: recognition by human T-cells and immunogenicity in Aotus monkeys. Ann. Bop. Med. Parasitol (1997) 91(3):253–265.
   Google Scholar
• LOPEZ JA, ROGGERO MA,DOUMBO O et al: Recognition of synthetic 104-mer and 102-mer peptides corresponding to the N- and C-terminal nonrepeat regions of the Plasmodium fakiparum circumsporozoite protein by sera from human donors. Am. I Bop. Med. Hyg. (1996) 55(4):424–429.
   PubMed Web of Science ®Google Scholar
• BLUM-TIROUVANZIAM U, SERVIS C, HABLUETZEL A et al.: Localization of HLA-A2.1 restricted T cell epitopes in the circumsporozoite protein of Plasmodium fakiparum. I Immunol (1995) 154(8):3922–3931.
   Google Scholar
• GONZALEZ JM, PETER K, ESPOSITO F et al: HLA-A*0201 restricted CD8+ T-lymphocyte responses to malaria: identification of new Plasmodium fakiparum epitopes by IFN-gamma ELISPOT. Parasite Immunol (2000) 22(10):501–514.
   PubMed Web of Science ®Google Scholar
• BONELO A, VALMORI D,TRIPONEZ F et al.: Generation and characterization of malaria-specific human CD8(+) lymphocyte clones: effect of natural polymorphism on T cell recognition and endogenous cognate antigen presentation by liver cells. Ear: Immunol (2000) 30(11):3079–3088.
   Google Scholar
• VALMORI D, PESSI A, BIANCHI E, CORRADIN G: Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. Immunol (1992) 149(2):717–721.
   Web of Science ®Google Scholar
• HERRERA S, DE PLATA C, GONZALEZ M et al:Antigenicity and immunogenicity of multiple antigen peptides (MAP) containing vivax CS epitopes in Aotus monkeys. Parasite Immunol (1997) 19(4):161–170.
   PubMed Web of Science ®Google Scholar
• HERRERA S, ESCOBAR P, DE PLATA C, AVILA GI, CORRADIN G,HERRERA MA: Human recognition of T cell epitopes on the Plasmodium vivax circumsporozoite protein. J. Immunol (1992) 148(12):3986–3990.
   PubMed Web of Science ®Google Scholar
• ARE VALO-HERRERAM,VALENCIA AZ, VERGARA J et al.: Identification of HLA-A2 restricted CD8(+) T-lymphocyte responses to Plasmodium vivax circumsporozoite protein in individuals naturally exposed to malaria. Parasite Immunol (2002) 24(3):161–169.
   Google Scholar
• MERALDI V, NEBIE. I, MORET R et al: Recognition of synthetic polypeptides corresponding to the N- and C-terminal fragments of Plasmodium fakiparum Exp-1 by T-cells and plasma from human donors from African endemic areas. Parasite Immunol (2002) 24(3):141–150.
   PubMed Web of Science ®Google Scholar
• DE STRICKER K, VUUST J, JEPSEN S, OEUVRAY C, THEISEN M: Conservation and heterogeneity of the glutamate-rich protein (GLURP) among field isolates and laboratory lines of Plasmodium fakiparum. Biochem. Parasitol (2000) 111(1):123–130.
   PubMed Web of Science ®Google Scholar
• THEISEN M, SOE S, JESSING SG et al: Identification of a major B-cell epitope of the Plasmodium falciparum glutamate-rich protein (GLURP), targeted by human antibodies mediating parasite killing. Vaccine (2000) 19(2-3):204–212.
   PubMed Web of Science ®Google Scholar
• THEISEN M, DODOO D, TOURE-BALDE A et al.: Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity. Infect. Immun. (2001) 69(9):5223–5229.
   PubMed Web of Science ®Google Scholar
• PERLAZA BL, SUAZET JP, BALDE AT et al.: Long synthetic peptides encompassing the Plasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice. Eur. Immunol (2001) 31(7):2200–2209.
   PubMed Web of Science ®Google Scholar
• KAMMERER R, CHVATCHKO Y, KETTNER A et al.: Modulation of T-cell response to phospholipase A2 and phospholipase A2-derived peptides by conventional bee venom immunotherapy. Allergy Clio. Immunol (1997) 100(1):96–103.
   PubMed Web of Science ®Google Scholar
• AKDIS CA, BLASER K: Mechanisms of allergen-specific immunotherapy. Allergy (2000) 55(6):522–530.
   PubMed Web of Science ®Google Scholar
• WINTHER L, MALLING HJ, MOSBECH H: Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects. Allergy (2000) 55(6):827–835.
   PubMedGoogle Scholar
• VON GARNIER C, ASTORI M, KETTNER A et al.: Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis. Eur: I Immunol (2000) 30(6):1638–1645.
   PubMed Web of Science ®Google Scholar
• ASTORI M, VON GARNIER C, KETTNER A, DUFOUR N,CORRADIN G, SPERTINI F: Inducing tolerance by intranasal administration of long peptides in naive and primed CBA/J mice. Immunol (2000) 165(6):3497–3505.
   Web of Science ®Google Scholar
• LOPEZ JA, WEILENMANN C, AUDRAN R et al.: A synthetic malaria vaccine elicits a potent CD8+ and CD4+ T lymphocyte immune response in humans. Implications for vaccination strategies. Eur. Immunol (2001) 31(7):1989–1998.
   Google Scholar
• STOUT JA, KESTER KE, KRZYCH U et al.: Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. (1998) 178(4):1139–1144.
   PubMed Web of Science ®Google Scholar
• MCCONKEY SJ, REECE WH, MOORTHY VS et al.: Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. (2003) 9(6):729–735.
   PubMed Web of Science ®Google Scholar
• WAND R, DOOLAN DL, LE TP et al: Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science (1998) 282(5388)476–480.
   Google Scholar
• AUDRAN R, CACHAT M, LURATI L et al.: Phase I malaria vaccine trial with along synthetic peptide derived from theMSP3 antigen 3. Infect. Inman. (2004) (In Press).
   Google Scholar
• KAMMERER R, KETTNER A, CHVATCHKO Y et al.: Delineation of PLA(2) epitopes using short or long overlapping synthetic peptides: interest for specific immunotherapy. Clin. Exp. Allergy (1997) 27(9):1016–1026.
   PubMed Web of Science ®Google Scholar
• FELLRATH JM, KETTNER A, DUFOUR N et al.: Allergen specific T cell tolerance induction with allergen-derived long peptides: results of a Phase I safety and immunogenicity trial.' Allergy Clin. Immunol (2003) 111(4):854–861.
   Google Scholar
• AKDIS CA, BLESKEN T, AKDIS M, WUTHRICH B, BLASER K: Role of interleukin 10 in specific immunotherapy. Clin. Invest. (1998) 102(1):98–106.
   Google Scholar
• VALERO MV, AMADOR LR, GALINDO C et al.: Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium fakipamm malaria in Colombia. Lancet (1993) 341(8847):705–710.
   PubMed Web of Science ®Google Scholar
• D'ALESSANDRO U, LEACH A, DRAKELEY CJ et al.: Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet (1995) 346(8973):462–467.
   Google Scholar
• NOSTEN F, LUXEMBURGER C, KYLE DE et al.: Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Lancet (1996) 348(9029):701–707.
   PubMed Web of Science ®Google Scholar